Five-Year Survivors From Brain Metastases Treated With Stereotactic Radiosurgery: Biology, Improving Treatments, or Just Plain Luck?

Authors

Jane B Pearce
Fang-Chi Hsu
Claire M Lanier
Christina K Cramer
Jimmy Ruiz
Hui-Wen Lo
Fei Xing
Margaret Smith
Wencheng Li
Christopher Whitlow
Jaclyn J White
Stephen B Tatter
Adrian W Laxton
Michael D Chan

Publication Date

4-1-2023

Journal

Neuro-Oncology-Practice

Abstract

BACKGROUND: Improvements in therapies have led to an increasing number of long-term survivors of brain metastases. The present series compares a population of 5-year survivors of brain metastases to a generalized brain metastases population to assess for factors attributable to long-term survival.

METHODS: A single institution retrospective review was performed to identify 5-year survivors of brain metastases who received stereotactic radiosurgery (SRS). A historical control population of 737 patients with brain metastases was used to assess similarities and differences between the long-term survivor population and the general population treated with SRS.

RESULTS: A total of 98 patients with brain metastases were found to have survived over 60 months. No differences between long-term survivors and controls were identified with regards to the age at first SRS (

CONCLUSION: Five-year survivors of brain metastases represent a diverse histologic population, suggesting a small population of oligometastatic and indolent cancers exist for each cancer type.

Keywords

brain metastasis, prolonged survival, neurologic death

Comments

Supplementary Material

PMID: 36970170

DOI

10.1093/nop/npac095

PMID

36970170

PMCID

PMC10037943

PubMedCentral® Posted Date

December 2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes